Presepsin – (sCD14-ST): an early marker of sepsis

Abstract

Sepsis remains the leading cause of death in intensive care units in all age groups around the world. Early diagnosis is key to achieving better results. Therefore, new biomarkers are certainly needed that could better inform clinicians treating such patients. Biomarkers can play an important role in this process because they can indicate the presence, absence, or severity of sepsis and can play a key role in providing supporting information to guide clinicians to prompt diagnosis and extend treatment beyond standard therapy. Presepsin is the N-terminal fragment of soluble CD14 subtype (sCD14-ST). Presepsin is a promising new marker for diagnosing and monitoring sepsis. It shows high specificity, confirmed by experimental and clinical studies. Presepsin appears to be the most promising new biomarker for early diagnosis of sepsis and at the same time an important prognostic biomarker. Presepsin is also a valuable tool for identifying patients at high risk of complications and in monitoring the progression of the disease.